The effect of cholinesterase inhibitor (ChEI) on mild cognitive impairment (MCI) is controversial. Brain age has been shown to predict Alzheimer’s disease conversion from MCI.
Objective:
The study aimed to show that brain age is related to cognitive outcomes of ChEI treatment in MCI.
Methods:
Brain MRI, the Clinical Dementia Rating (CDR) and Mini-Mental State Exam (MMSE) scores were retrospectively retrieved from a ChEI treatment database. Patients who presented baseline CDR of 0.5 and received ChEI treatment for at least 2 years were selected. Patients with stationary or improved cognition as verified by the CDR and MMSE were categorized to the ChEI-responsive group, and those with worsened cognition were assigned to the ChEI-unresponsive group. A gray matter brain age model was built with a machine learning algorithm by training T1-weighted MRI data of 362 healthy participants. The model was applied to each patient to compute predicted age difference (PAD), i.e. the difference between brain age and chronological age. The PADs were compared between the two groups.
Results:
58 patients were found to fit the ChEI-responsive criteria in the patient data, and 58 matched patients that fit the ChEI-unresponsive criteria were compared. ChEI-unresponsive patients showed significantly larger PAD than ChEI-responsive patients (8.44±8.78 years versus 3.87±9.02 years, p = 0.0067).
Conclusions:
Gray matter brain age is associated with cognitive outcomes after 2 years of ChEI treatment in patients with the CDR of 0.5. It might facilitate the clinical trials of novel therapeutics for MCI.
NicholsE, SteinmetzJD, VollsetSE, FukutakiK, ChalekJ, Abd-AllahF, AbdoliA, AbualhasanA, Abu-GharbiehE, AkramTT, et al.(2022) Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: An analysis for the Global Burden of Disease Study 2019. Lancet Public Health7, e105–e125.
PozziFE, ContiE, AppollonioI, FerrareseC, TremolizzoL (2022) Predictors of response to acetylcholinesterase inhibitors in dementia: A systematic review. Front Neurosci16, 998224.
8.
WattmoC, WallinÅK, LondosE, MinthonL (2011) Long-term outcome and prediction models of activities of daily living in Alzheimer disease with cholinesterase inhibitor treatment. Alzheimer Dis Assoc Disord25, 63–72.
Tábuas-PereiraM, BaldeirasI, DuroD, SantiagoB, RibeiroM, LeitãoM, OliveiraC, SantanaI (2016) Prognosis of early-onset vs. late-onset mild cognitive impairment: Comparison of conversion rates and its predictors. Geriatrics1, 11.
11.
PetersenRC, LopezO, ArmstrongMJ, GetchiusTSD, GanguliM, GlossD, GronsethGS, MarsonD, PringsheimT, DayGS, SagerM, StevensJ, Rae-GrantA (2018) Practice guideline update summary: Mild cognitive impairment: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology90, 126–135.
12.
LeeJ, HowardRS, SchneiderLS (2022) The current landscape of prevention trials in dementia. Neurotherapeutics19, 228–247.
13.
HanJ, BesserLM, XiongC, KukullWA, MorrisJC (2019) Cholinesterase inhibitors may not benefit mild cognitive impairment and mild Alzheimer disease dementia. Alzheimer Dis Assoc Disord33, 87–94.
14.
KasperS, BancherC, EckertA, FörstlH, FrölichL, HortJ, KorczynAD, KressigRW, LevinO, PalomoMSM (2020) Management of mild cognitive impairment (MCI): The need for national and international guidelines. World J Biol Psychiatry21, 579–594.
15.
ColeJH, FrankeK (2017) Predicting age using neuroimaging: Innovative brain ageing biomarkers. Trends Neurosci40, 681–690.
16.
MishraS, BeheshtiI, KhannaP (2023) A review of neuroimaging-driven brain age estimation for identification of brain disorders and health conditions. IEEE Rev Biomed Eng16, 371–385.
17.
BeheshtiI, MaikusaN, MatsudaH (2018) The association between“Brain-Age Score” (BAS) and traditional neuropsychologicalscreening tools in Alzheimerမs disease. Brain Behav8, e01020.
18.
ChenC-L, ShihY-C, LiouH-H, HsuY-C, LinF-H, TsengW-YI (2019) Premature white matter aging in patients with right mesial temporal lobe epilepsy: A machine learning approach based on diffusion MRI data. Neuroimage Clin24, 102033.
19.
ChenC-L, HwangT, TungY-H, YangL-Y, HsuY-C, LiuC, LinY-T, HsiehM-H, LiuC-C, ChienY-L, HwuH, TsengW-YI (2022) Detection of advanced brain aging in schizophrenia and its structural underpinning by using normative brain age metrics. Neuroimage Clin34, 103003.
20.
ChenC-L, KuoM-C, WuW-C, HsuY-C, WuR-M, TsengW-YI (2022) Advanced brain aging in multiple system atrophy compared to Parkinsonမs disease. Neuroimage Clin34, 102997.
21.
ColeJH, LeechR, SharpDJ,
the Alzheimerမs Disease Neuroimaging Initiative
(2015) Prediction of brain age suggests accelerated atrophy after traumatic brain injury. Ann Neurol77, 571–581.
22.
FrankeK, GaserC, ManorB, NovakV (2013) Advanced BrainAGE in older adults with type 2 diabetes mellitus. Front Aging Neurosci5, 90.
23.
KoutsoulerisN, DavatzikosC, BorgwardtS, GaserC, BottlenderR, FrodlT, FalkaiP, Riecher-RosslerA, MollerH-J, ReiserM, PantelisC, MeisenzahlE (2014) Accelerated brain aging in schizophrenia and beyond: A neuroanatomical marker of psychiatric disorders. Schizophr Bull40, 1140–1153.
24.
RonanL, Alexander-BlochAF, WagstylK, FarooqiS, BrayneC, TylerLK, Cam-CAN, FletcherPC (2016) Obesity associated with increased brain age from midlife. Neurobiol Aging47, 63–70.
25.
LaMontagnePJ, BenzingerTLs, MorrisJC, KeefeS, HornbeckR, XiongC, GrantE, HassenstabJ, MoulderK, VlassenkoAG, RaichleME, CruchagaC, MarcusD (2019) OASIS-3: Longitudinal Neuroimaging, Clinical, and Cognitive Dataset for Normal Aging and Alzheimer Disease. medRxiv, doi:https://doi.org/10.1101/2019.12.13.19014902 [Preprint]. Posted December 15, 2019.
26.
HughesCP, BergL, DanzigerW, CobenLA, MartinRL (1982) A new clinical scale for the staging of dementia. Br J Psychiatry140, 566–572.
27.
TsengW-YI, HsuY-C, KaoT-W (2022) Brain age difference at baseline predicts clinical dementia rating change in approximately two years. J Alzheimers Dis86, 613–627 .
28.
GaserC, FrankeK, KlöppelS, KoutsoulerisN, SauerH,
Alzheimerမs Disease Neuroimaging Initiative
(2013) BrainAGE in mild cognitive impaired patients: Predicting the conversion to Alzheimerမs disease. PLoS One8, e67346.
29.
WangJ, KnolMJ, TiulpinA, DubostF, De BruijneM, VernooijMW, AdamsHHH, IkramMA, NiessenWJ, RoshchupkinGV (2019) Gray matter age prediction as a biomarker for risk of dementia. Proc Natl Acad Sci U S A116, 21213–21218.
30.
BiondoF, JewellA, PritchardM, AarslandD, StevesCJ, MuellerC, ColeJH (2022) Brain-age is associated with progression to dementia in memory clinic patients. Neuroimage Clin36, 103175.
31.
HampelH, MesulamM-M, CuelloAC, FarlowMR, GiacobiniE, GrossbergGT, KhachaturianAS, VergalloA, CavedoE, SnyderPJ, KhachaturianZS (2018) The cholinergic system in the pathophysiology and treatment of Alzheimerမs disease. Brain141, 1917–1933.
32.
FolsteinMF, FolsteinSE, McHughPR (1975) “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res12, 189–198.
BegMF, MillerMI, TrouvéA, YounesL (2005) Computing large deformation metric mappings via geodesic flows of diffeomorphisms. Int J Comput Vis61, 139–157.
35.
MillerMI, TrouvéA, YounesL (2006) Geodesic shooting for computational anatomy. J Math Imaging Vis24, 209–228.
36.
RosenbaumPR, RubinDB (1983) The central role of the propensity score in observational studies for causal effects. Biometrika70, 41–55.
37.
WattmoC (2013) Prediction models for assessing long-term outcome in Alzheimerမs disease: A review. Am J Alzheimers Dis Dementiasr28, 440–449.
38.
KimKW, MacFallJR, PayneME (2008) Classification of white matter lesions on magnetic resonance imaging in elderly persons. Biol Psychiatry64, 273–280.
39.
FazekasF, ChawlukJ, AlaviA, HurtigH, ZimmermanR (1987) MR signal abnormalities at 1.5 T in Alzheimerမs dementia and normal aging. Am J Roentgenol149, 351–356.
40.
ChengY-W, ChenT-F, ChengT-W, LaiY-M, HuaM-S, ChenY-F, ChiuM-J (2015) Hippocampal atrophy but not white-matter changes predicts the long-term cognitive response to cholinesterase inhibitors in Alzheimerမs disease. Alzheimers Res Ther7, 72.
41.
JiangH, GuoJ, DuH, XuJ, QiuB (2019) Transfer learning on T1-weighted images for brain age estimation. Math Biosci Eng16, 4382–4398.
42.
ChenC-L, HsuY-C, YangL-Y, TungY-H, LuoW-B, LiuC-M, HwangT-J, HwuH-G, IsaacTseng W-Y (2020) Generalization of diffusion magnetic resonance imaging–based brain age prediction model through transfer learning. Neuroimage217, 116831.
43.
ColeJH (2020) Multimodality neuroimaging brain-age in UK biobank: Relationship to biomedical, lifestyle, and cognitive factors. Neurobiol Aging92, 34–42.
44.
FrankeK, GaserC (2019) Ten years of BrainAGE as a neuroimaging biomarker of brain aging: What insights have we gained?Front Neurol10, 789.
45.
SallowayS, ChalkiasS, BarkhofF, BurkettP, BarakosJ, PurcellD, SuhyJ, ForrestalF, TianY, UmansK, WangG, SinghalP, Budd HaeberleinS, SmirnakisK (2022) Amyloid-related imaging abnormalities in 2 phase 3 studies evaluating aducanumab in patients with early Alzheimer disease. JAMA Neurol79, 13.
Wada-IsoeK, KikuchiT, Umeda-KameyamaY, MoriT, AkishitaM, NakamuraY, ABC Dementia Scale Research Group
(2019) Global clinical dementia rating score of 0.5 may not be an accurate criterion to identify individuals with mild cognitive impairment. J Alzheimers Dis Rep3, 233–239.
48.
CacabelosR (2020) Pharmacogenetic considerations when prescribing cholinesterase inhibitors for the treatment of Alzheimerမs disease. Expert Opin Drug Metab Toxicol16, 673–701.
